Oral Answers to Questions Debate
Full Debate: Read Full DebateDepartment: Department of Health and Social Care
Caroline Johnson
Main Page: Caroline Johnson (Conservative - Sleaford and North Hykeham)Department Debates - View all Caroline Johnson's debates with the Department of Health and Social Care
(1 day, 7 hours ago)
Commons ChamberRead Full debate Read Hansard Text Watch Debate Read Debate Ministerial Extracts
Dr Caroline Johnson (Sleaford and North Hykeham) (Con)
I declare an interest as a consultant paediatrician in the NHS. Prevention of ill health is crucial. It is particularly important in children, perhaps most especially when one is trying to prevent ill health in children caused by doctors. I have expressed concerns previously about the puberty blockers trial, as have many in both Houses. The trial has now been paused due to a Medicines and Healthcare products Regulatory Agency letter. When were Ministers first aware of that letter and when were they first aware of the concerns described within it?
Ashley Dalton
The regulators are doing their job. This is a perfectly ordinary occurrence in certain research trials. As the hon. Member has made the House aware—I am sure it was already aware—the trial has been paused. We will leave the regulators and the clinicians to do their jobs to ensure that all the trials, including this one, are done in an appropriate fashion.
Dr Johnson
That is a very interesting answer. Before Christmas, the Secretary of State had confidence in an allegedly vigorous and rigorous process. Fertility preservation techniques have not deteriorated over the last few months. The ages at which children reach the Tanner stages of puberty have not changed over the last few months, but the MHRA’s view has. Why? Given that this is such a scrutinised trial, does that not call into question the MHRA’s wider competence and due diligence? Will the Minister publish the MHRA’s letter from November referred to in the more recent correspondence published on Friday?
Ashley Dalton
What the hon. Member highlights is part of this rigorous process. That is what happens. Why the MHRA has changed its view is a question for the MHRA, but it is up to the MHRA to raise these issues through the process. That is why we run such trials. [Interruption.] It is an independent regulator.